Status:
COMPLETED
Study to Determine the Efficacy and Safety of Docetaxel and Doxorubicin With INGN 201 in Locally Advanced Breast Cancer
Lead Sponsor:
Introgen Therapeutics
Conditions:
Locally Advanced Breast Cancer (LABC)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A maximum of 60 subjects will be enrolled in the trial. It is a non-randomized, open label, single center study. All subjects undergo INGN 201 injection and IV chemotherapy: doxorubicin and docetaxel....
Eligibility Criteria
Inclusion
- Documented late stage breast cancer: stage III A-B (excluding inflammatory breast carcinoma) or localized stage IV breast cancer
- Male or female
- 18 years or older
- Adequate bone marrow, liver, and kidney function
Exclusion
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00286247
Last Update
April 1 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
M.D. Anderson Cancer Center
Houston, Texas, United States, 77030